Literature DB >> 8864998

Predicted and actual BCNU concentrations in normal rabbit brain during intraarterial and intravenous infusions.

S J Hassenbusch1, J H Anderson, O M Colvin.   

Abstract

Normal New Zealand White rabbits were used to compare theoretical brain concentrations (based upon pharmacokinetic modeling) with actual experimental concentrations of BCNU following intraarterial (IA) or intravenous (IV) infusions. IA infusion therapy for brain tumor patients has been promising based upon theoretical predictions but of limited effectiveness clinically. Experimentally-measured rabbit carotid artery flow rates (63.9 +/- 3.4 ml/min) [mean +/- 1 sem] and BCNU systemic clearances (197 +/- 10.2 ml/min) predicted a theoretical IA advantage of 4.1 +/- 0.2. Ipsilateral brain concentrations of BCNU during and after IA infusions (20 mg/min/m2 over 15 minutes) were: 16.2 +/- 2.9, 19.0 +/- 3.9, 20.3 +/- 2.8, 4.8 +/- 2.5, 2.1 +/- 1.5, and 1.7 +/- 1.6 micrograms/gm brain at 5, 10, 15, 25, 35, and 45 minutes after infusion start. Mean concentrations at same time points in contralateral hemisphere (IA infusions) were: 7.1 +/- 1.8, 9.0 +/- 1.8, 10.3 +/- 0.7, 4.2 +/- 1.4, 2.2 +/- 1.2, 2.0 +/- 1.5 micrograms/gm brain. Concentrations in either hemisphere during IV infusions were similar to contralateral hemisphere during IA infusions. Comparison of ipsilateral: contralateral hemisphere ratios during and after IA infusions were: 3.2 +/- 0.4, 2.6 +/- 0.3, 2.2 +/- 0.3, 1.1 +/- 0.3, 1.0 +/- 0.4, and 0.9 +/- 0.3 at the same time points. Although these data show higher drug concentrations with IA infusions, actual values were considerably less than predicted by theoretical modeling. This discrepancy between theoretical and experimental results emphasizes need for further study of causes and remedies so that IA therapy can achieve better drug concentrations with less toxicity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8864998     DOI: 10.1007/bf00177438

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  41 in total

1.  Combined intra-arterial chemotherapy followed by radiation in astrocytomas.

Authors:  K Watne; E Hannisdal; O Nome; B Hager; K Wester; M Heier; H Hirschberg
Journal:  J Neurooncol       Date:  1992-09       Impact factor: 4.130

2.  Colorimetric method for the determination of 1,3-bis(2-chloroethyl)-1-nitrosourea.

Authors:  T L Loo; R L Dion
Journal:  J Pharm Sci       Date:  1965-05       Impact factor: 3.534

3.  Intra-arterial BCNU chemotherapy for malignant gliomas.

Authors:  S H Foo; J Ransohoff; A Berenstein; I S Choy
Journal:  J Neurosurg       Date:  1985-03       Impact factor: 5.115

4.  Analysis for nitrosourea antitumor agents by gas chromatography--mass spectrometry.

Authors:  R G Smith; S C Blackstock; L K Cheung; T L Loo
Journal:  Anal Chem       Date:  1981-07       Impact factor: 6.986

5.  A pilot clinical and pharmacokinetic study of intracarotid cisplatin and bleomycin.

Authors:  L G Feun; N Savaraj; Y Y Lee; H Landy; J Martinez-Prieto; C Charnsangavej; J D Post; K F Lee; S Wallace; B Bowen
Journal:  Sel Cancer Ther       Date:  1991

6.  The pharmacology of diaziquone given in intravenous or intracarotid infusion to normal and intracranial tumor-bearing puppies.

Authors:  M J Egorin; E H Bellis; M Salcman; J M Collins; J F Spiegel; N R Bachur
Journal:  J Neurosurg       Date:  1984-05       Impact factor: 5.115

7.  Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas.

Authors:  H B Newton; J Bromberg; L Junck; M A Page; H S Greenberg
Journal:  J Neurooncol       Date:  1993-03       Impact factor: 4.130

8.  Hemorrhagic encephalitis produced by selective non-occlusive intracarotid BCNU injection in dogs.

Authors:  M F Omojola; A J Fox; R N Auer; F V Viñuela
Journal:  J Neurosurg       Date:  1982-12       Impact factor: 5.115

9.  Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.

Authors:  H S Greenberg; W D Ensminger; W F Chandler; P B Layton; L Junck; J Knake; A K Vine
Journal:  J Neurosurg       Date:  1984-09       Impact factor: 5.115

10.  Visual toxicity following intra-arterial chemotherapy with hydroxyethyl-CNU in patients with malignant gliomas. A prospective study with statistical analysis.

Authors:  G Defer; F Fauchon; M Schaison; J Chiras; P Brunet
Journal:  Neuroradiology       Date:  1991       Impact factor: 2.804

View more
  6 in total

Review 1.  Intra-arterial chemotherapy for malignant gliomas: a critical analysis.

Authors:  J-K Burkhardt; H A Riina; B J Shin; J A Moliterno; C P Hofstetter; J A Boockvar
Journal:  Interv Neuroradiol       Date:  2011-10-17       Impact factor: 1.610

2.  A murine model of targeted infusion for intracranial tumors.

Authors:  Minhyung Kim; Tara A Barone; Natalia Fedtsova; Anatoli Gleiberman; Chandler D Wilfong; Julie A Alosi; Robert J Plunkett; Andrei Gudkov; Joseph J Skitzki
Journal:  J Neurooncol       Date:  2015-09-16       Impact factor: 4.130

Review 3.  Intracarotid delivery of drugs: the potential and the pitfalls.

Authors:  Shailendra Joshi; Phillip M Meyers; Eugene Ornstein
Journal:  Anesthesiology       Date:  2008-09       Impact factor: 7.892

4.  DTI-015 produces cures in T9 gliosarcoma.

Authors:  Dennis Pietronigro; Frank Drnovsky; Humberto Cravioto; Joseph Ransohoff
Journal:  Neoplasia       Date:  2003 Jan-Feb       Impact factor: 5.715

5.  Transient cerebral hypoperfusion enhances intraarterial carmustine deposition into brain tissue.

Authors:  Shailendra Joshi; Mei Wang; Joshua J Etu; Raymond F Suckow; Thomas B Cooper; Steven J Feinmark; Jeffrey N Bruce; Robert L Fine
Journal:  J Neurooncol       Date:  2007-07-17       Impact factor: 4.506

Review 6.  Intra-arterial chemotherapy of primary brain tumors.

Authors:  Herbert B Newton
Journal:  Curr Treat Options Oncol       Date:  2005-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.